ThyraMirTM microRNA classifier test for Thyroid Nodules Now Available Through LabCorp

January 12, 2016

PARSIPPANY, N.J., Jan. 12, 2016 /PRNewswire/ — Interpace Diagnostics (NASDAQ: IDXG) announced today that Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), the world’s leading health care diagnostics company, will begin offering Interpace’s new ThyraMirTM microRNA classifier test.  Physicians will be able to order ThyraMir through LabCorp, in addition to Interpace’s ThyGenX® oncogene panel, which LabCorp already […]

Read the full article →

MicroRNA Therapeutic Candidate for the Treatment of NASH in Patients with Type 2 Diabetes/Pre-Diabetes, Enters Phase I Clinical Development

December 18, 2015

Regulus Earns $10.0 Million Milestone Payment from AstraZeneca and Achieves Key Goal for 2015 LA JOLLA, Calif., Dec. 18, 2015 /PRNewswire/ — Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-125(AZD4076), by […]

Read the full article →

Upcoming Abcam Webinar: MicroRNAs as biomarkers and therapeutic targets negative breast cancer

December 18, 2015

Upcoming Live Webinar and Q&A Session with Dr Brian D. Adams of Harvard Medical School and sponsorde by Abcam: “MicroRNAs as biomarkers and therapeutic targets in triple negative breast cancer” January 21, 2016 | 11:00am EST/ 8:00am PST Register here Triple negative breast cancer accounts for a disproportionate share of the total breast cancer morbidity […]

Read the full article →

DASHR: a new database of small human non-coding RNAs

November 20, 2015

Description:  Small non-coding RNAs (sncRNAs) are highly abundant RNAs, typically <100 nucleotides long, that act as key regulators of diverse cellular processes. Although thousands of sncRNA genes are known to exist in the human genome, no single database provides searchable, unified annotation, and expression information for full sncRNA transcripts and mature RNA products derived from […]

Read the full article →

Regulus Announces Grant of Patents Covering Lead microRNA Therapeutics

November 12, 2015

LA JOLLA, Calif., Nov. 12, 2015 /PRNewswire/ — Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs (miR), today announced that the U.S. Patent and Trademark Office (“USPTO”) has granted patents related to Regulus’ most advanced microRNA therapeutics, RG-101, the company’s wholly-owned, GalNAc-conjugated anti-miR-122 being developed to treat […]

Read the full article →

miRagen Therapeutics Initiates First Clinical Trial for Anti-Fibrosis Product Candidate MRG-201

November 12, 2015

BOULDER, Colorado, – November 12, 2015 – miRagen Therapeutics, Inc. a biopharmaceutical company developing innovative microRNA-based therapeutics, today announced that it has initiated a Phase 1 clinical study of MRG-201, a synthetic microRNA mimic (promiR) to microRNA-29b.  The Phase 1 trial is being conducted in normal healthy volunteers and may be extended to patients suffering from cutaneous […]

Read the full article →

RG-101 Update: Regulus Expands Development of RG-101 through Clinical Trial Collaboration with GSK

November 3, 2015

Long-Acting Parenteral Formulation of GSK2878175 Being Developed; Co-Administration with RG-101 May Enable Single Visit Therapy for HCV Patients LA JOLLA, Calif., Nov. 3, 2015 /PRNewswire/ — Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs (miR), today announced that it has expanded development of RG-101, Regulus’ wholly-owned, […]

Read the full article →

New standard for miRNA annotations published in Annual Reviews of Genetics

November 2, 2015

MicroRNAs (miRNAs) are a novel class of gene regulators that are now the center of their own research field in human cancer: the non-coding RNA field. MiRNAs are ~22nt long non-coding RNA transcripts that derive from hairpin precursors and regulate gene-expression of target genes by inhibiting the protein production of the target genes’ messenger RNA […]

Read the full article →

Regulus Achieves All Research Milestones in Collaboration with Biogen to Identify microRNA Biomarkers for Multiple Sclerosis

October 28, 2015

LA JOLLA, Calif., Oct. 28, 2015 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has earned a fourth milestone payment in its collaboration with Biogen (NASDAQ: BIIB) related to progress in the companies’ research collaboration to identify microRNAs as biomarkers for multiple […]

Read the full article →

Abcam Webinar: Developing Durable miRNA Biomarker Technologies for Microbial Carcinogenesis in Resource Poor Settings

October 28, 2015

Abcam is hosting a free webinar titled “Developing durable miRNA biomarker technologies for microbial carcinogenesis in resource poor settings”. Live Webinar Details Wednesday, November 4, 2015 16:00-17:00 CET/ 15:00-16:00 GMT/ 10:00-11:00 EST/ 07:00-08:00 PST Register here: http://www.abcam.com/mirnaprofilingwebinar Webinar Summary: Currently, more than half of the global cancer burden occurs in low-and middle-income countries, with 40% […]

Read the full article →